Assessing The Manufacturability Of Prospective Lead mRNA Candidates
In this Bioprocess Online Live panel discussion, John Stubenrauch, Ph.D., Chief Operations Officer at Nutcracker Therapeutics, Hari Pujar, Ph.D., Chief Operating Officer at Tessera, and Anna Rose Welch, Chief Editor at Cell & Gene Collaborative discuss go-to best practices, suggestions, and experiences for prioritizing and streamlining technical operations endeavors to prepare for the clinic and, eventually, the commercial market. Here, Stubenrauch and Pujar share the most important factors to consider when assessing the manufacturability of novel linear mRNA candidates in order to bring forward the most successful lead candidates.
View the full presentation here.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.